Latham & Watkins

Helping Private Equity dealmaking evolve.

Network Bio develops a platform that serves as a centralized repository for clinical and molecular data. This enables researchers to identify patterns and correlations, facilitating precision medicine approaches for common human diseases.

Reynen Court LLC is a technology company that provides a platform designed to assist law firms and corporate legal departments in adopting and managing legal technology tools. Founded in 2018 and headquartered in Amsterdam, with an additional office in Piedmont, California, Reynen Court enables users to securely access and utilize third-party software applications for tasks such as contract analysis, discovery, and practice management. The platform features a solution store and a control panel that simplifies the management of modern cloud-based applications, allowing firms to handle subscriptions and provisioning efficiently. Additionally, it enhances interoperability among various legal technology applications, facilitating the integration of artificial intelligence and smart contracts while protecting sensitive firm and client information from exposure to external cloud environments.

Founded in 2017, Drizzlex Ltd specializes in smart water management solutions for multi-family properties. Its flagship product, DrizzleX, combines IoT-based smart sensors with a SaaS dashboard to monitor and analyze water usage, empowering tenants to conserve water and enabling property managers to reduce bills by up to 40%. With installations across California, Nevada, Arizona, and New York, the company aims to promote water conservation and sustainability.

KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California. KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.